Absolute cardiovascular disease risk assessment

Similar documents
Absolute cardiovascular disease risk management

Absolute cardiovascular disease risk

Heart and stroke risk: a catalyst for conversation

HeartScore Web - based version users guide TABLE OF CONTENTS. 1. Preamble Benefits of using HeartScore Accessing HeartScore...

DISCLOSURES RISK ASSESSMENT. Stroke and Heart Disease -Is there a Link Beyond Risk Factors? Daniel Lackland, MD

Heart information. Cardiac rehabilitation

Diabetic nephropathy is detected clinically by the presence of persistent microalbuminuria or proteinuria.

Cardiovascular risk assessment: Audit findings from a nurse clinic a quality improvement initiative

Diabetes and the Kidneys

Calculating the stage of Renal Disease

High Blood Pressure and Chronic Kidney Disease

High Blood Cholesterol

Identifying and treating long-term kidney problems (chronic kidney disease)

Understanding diabetes Do the recent trials help?

HIGH BLOOD PRESSURE AND YOUR KIDNEYS

Cardiovascular Risk in Diabetes

Metabolic Syndrome Overview: Easy Living, Bitter Harvest. Sabrina Gill MD MPH FRCPC Caroline Stigant MD FRCPC BC Nephrology Days, October 2007

Your Results. For more information visit: Name: Date: In partnership with

Coronary Heart Disease (CHD) Brief

Managing diabetes in the post-guideline world. Dr Helen Snell Nurse Practitioner PhD, FCNA(NZ)

2016 PQRS OPTIONS FOR INDIVIDUAL MEASURES: CLAIMS, REGISTRY

Australian heart disease statistics 2014

High Blood Pressure (Essential Hypertension)

Risk estimation and the prevention of cardiovascular disease. A national clinical guideline

Know your Numbers The D5 Goals for Diabetes Care. Shelly Hanson RN, CNS, CDE Cuyuna Regional Medical Center November 6, 2014

MANAGEMENT OF LIPID DISORDERS: IMPLICATIONS OF THE NEW GUIDELINES

Cohort Studies. Sukon Kanchanaraksa, PhD Johns Hopkins University

OEM MAXNIBP Frequently Asked Questions

Systolic Blood Pressure Intervention Trial (SPRINT) Principal Results

Cardiovascular disease physiology. Linda Lowe-Krentz Bioscience in the 21 st Century October 14, 2011

PHARMACOLOGICAL Stroke Prevention in Atrial Fibrillation STROKE RISK ASSESSMENT SCORES Vs. BLEEDING RISK ASSESSMENT SCORES.

3.5% 3.0% 3.0% 2.4% Prevalence 2.0% 1.5% 1.0% 0.5% 0.0%

How To Treat Dyslipidemia

G:\ CDM\BHCIG Diabetes Pathway FINAL September 05.doc 1

HEALTH MANAGEMENT PLAN PROGRAMME

What is a Heart Attack? 1,2,3

ADVANCE: a factorial randomised trial of blood pressure lowering and intensive glucose control in 11,140 patients with type 2 diabetes

The Canadian Association of Cardiac

High Blood Pressure and Your Kidneys

Case study 28: Managing hypertension in diabetes

SUMMARY OF CHANGES TO QOF 2015/16 - ENGLAND CLINICAL

Clinical Decision Support: The Basics

75 YEARS OF WORKING TO BUILD A HEALTHY AUSTRALIA NHMRC

Underwriting Critical Illness Insurance: A model for coronary heart disease and stroke

Aggressive Lowering of Blood Pressure in type 2 Diabetes Mellitus: The Diastolic Cost

Chronic Kidney Disease and Diabetes

Mortality Assessment Technology: A New Tool for Life Insurance Underwriting

Obesity in the United States Workforce. Findings from the National Health and Nutrition Examination Surveys (NHANES) III and

Information Guide Booklet. Life Insurance

Living Expenses Cover

Chronic diseases in low and middle income countries: more research or more action? Shah Ebrahim London School of Hygiene & Tropical Medicine

What are the PH interventions the NHS should adopt?

Diabetes and Hypertension Care For Adults in Primary Care Settings

High Blood Pressure and Chronic Kidney Disease. For People With CKD Stages 1 4

High Blood pressure and chronic kidney disease

NHS Diabetes Prevention Programme (NHS DPP) Non-diabetic hyperglycaemia. Produced by: National Cardiovascular Intelligence Network (NCVIN)

Scottish Diabetes Survey Scottish Diabetes Survey Monitoring Group

Insulin is a hormone produced by the pancreas to control blood sugar. Diabetes can be caused by too little insulin, resistance to insulin, or both.

Appendix: Description of the DIETRON model

RAW PREVALENCE FOR NORTHERN IRELAND AS AT 31 MARCH 2014

National Assembly for Wales: Health and Social Care Committee

Appendix. Appendix Figure 1: Trends in age-standardized cardiometabolic (CVD and diabetes) mortality by country.

UNIVERSITY OF BIRMINGHAM AND UNIVERSITY OF YORK HEALTH ECONOMICS CONSORTIUM (NICE EXTERNAL CONTRACTOR) Health economic report on piloted indicator(s)

Information Guide For GPs and Practice Nurses

Clinical Quality Measure Crosswalk: HEDIS, Meaningful Use, PQRS, PCMH, Beacon, 10 SOW

National Diabetes Audit and Report 1: Care Processes and Treatment Targets. Version 1.0 Published: 28 January 2016

Trend tables. Health Survey for England. A survey carried out on behalf of the Health and Social Care Information Centre. Joint Health Surveys Unit

Creating a culture of wellbeing in

Vascular Risk Reduction: Addressing Vascular Risk

Diabetes and Heart Disease

MY TYPE 2 DIABETES NUMBERS

Epidemiology of Hypertension 陈 奕 希 李 禾 园 王 卓

Summary of QOF indicators

High Blood Pressure in People with Diabetes:

International Task Force for Prevention Of Coronary Heart Disease. Clinical management of risk factors. coronary heart disease (CHD) and stroke

The benefits of prevention: healthy eating and active living

BMJ Open. Secondary Subject Heading: Epidemiology, Public health, Cardiovascular medicine

How To Know If You Have Microalbuminuria

Type 1 Diabetes ( Juvenile Diabetes)

Cardiovascular Disease Risk Factors

Stroke: Major Public Health Burden. Stroke: Major Public Health Burden. Stroke: Major Public Health Burden 5/21/2012

Guidelines for the management of hypertension in patients with diabetes mellitus

Multiple comorbidities: additive and predictive of cardiovascular risk. Peter M. Nilsson Lund University University Hospital Malmö, Sweden

Quantifying Life expectancy in people with Type 2 diabetes

African Americans & Cardiovascular Diseases

Barriers to Healthcare Services for People with Mental Disorders. Cardiovascular disorders and diabetes in people with severe mental illness

TYPE 2 DIABETES MELLITUS: NEW HOPE FOR PREVENTION. Robert Dobbins, M.D. Ph.D.

How To Calculate Type 1 Diabetes In Australia

THE NHS HEALTH CHECK AND INSURANCE FREQUENTLY ASKED QUESTIONS

Fewer people with coronary heart disease are being diagnosed as compared to the expected figures.

PREFERRED UNDERWRITING CLASSIFICATIONS

DIABETES YOUR GUIDE TO

Healthy Blood Pressure Healthy Heart Beat. Initiated by the World Hypertension League

Cardiovascular Disease Risk Assessment. Updated 2013

High Blood Pressure and Your Kidneys

what is diabetes? What actually goes wrong? Talking diabetes No.42

2016 PQRS OPTIONS FOR INDIVIDUAL MEASURES: CLAIMS, REGISTRY

Diabetes and Your Kidneys

Drug treatment of elevated blood pressure

Psoriasis Co-morbidities: Changing Clinical Practice. Theresa Schroeder Devere, MD Assistant Professor, OHSU Dermatology. Psoriatic Arthritis

Transcription:

Quick reference guide for health professionals Absolute cardiovascular disease risk assessment This quick reference guide is a summary of the key steps involved in assessing absolute cardiovascular risk (otherwise known as heart and stroke risk). It is based on the National Vascular Disease Prevention Alliance s Guidelines for the assessment of absolute cardiovascular disease risk,* available at www.heartfoundation.org.au. An initiative of the National Vascular Disease Prevention Alliance The NVDPA is a group of four leading and well-known Australian charities: Kidney Health Australia, Diabetes Australia, the National Heart Foundation of Australia and the National Stroke Foundation. It was established in 2000 and aims to reduce cardiovascular disease in Australia. Links to the full guidelines can be found on NVDPA member websites: www.strokefoundation.com.au, www.kidney.org.au, www.diabetesaustralia.com.au and www.heartfoundation.org.au. Why use an absolute risk approach? Cardiovascular absolute risk assessment is a simple tool that can enhance your clinical judgement, and improve your ability to educate and motivate patients. Single risk factors (like cholesterol level) provide a poor estimate of a patient s CVD risk. Absolute risk assessment provides a more accurate estimate of overall, individualised CVD risk, thereby allowing the clinician to best tailor pharmaceutical and lifestyle management to the patient. Professor Mark Harris, Royal Australian College of General Practitioners, University of New South Wales Comprehensive risk assessments, using an absolute risk approach, help GPs to effectively manage their patient s cardiovascular disease (CVD)* risk by providing a meaningful and individualised risk level. The absolute risk approach is emphasised by several Australian and international primary care guidelines, and recommended by experts. The probability that an individual will develop CVD within a given period of time depends on the combination and intensity of all identified risk factors, rather than on the presence of any single risk factor. Using an absolute risk approach takes into account the cumulative and sometimes synergistic effects of these multiple risk factors. Clinical decisions based on absolute CVD risk levels can lead to improved health outcomes, because they direct the right treatments to those who can benefit most. 1,2 Your patient s absolute risk what it means Absolute risk is the numerical probability of an event occurring within a specified period, expressed as a percentage. For example, if your patient s risk is 15%, there is a 15% probability that they will experience a cardiovascular event within 5 years. What about relative risk? Relative risk is a ratio of the rate of events in the population exposed to a risk factor compared with the rate among the population not exposed to this risk factor. Relative risk tells you little about your patient s actual risk. * CVD refers collectively to coronary heart disease, stroke and other vascular disease, including peripheral arterial disease and renovascular disease. Page 1

Assessment algorithm Cardiovascular risk tools enhance your clinical judgement of a patient s absolute cardiovascular risk. Use the below algorithm and charts on pages 4 and 5 to calculate absolute risk. Identify target group for assessment: All adults 45 74 years without known history of CVD. Aboriginal and Torres Strait Islander adults aged 35 years or older. See page 6 for additional considerations. Already known to be at increased risk? (See Box 2 on page 6.) Yes No Identify all other CVD risk factors (see Box 1 on page 3). Provide appropriate lifestyle advice. Commence intensive management of all risk factors (refer to relevant management guidelines). Conduct formal absolute risk assessment Calculate risk level using Framingham Risk Equation: Australian cardiovascular risk charts on pages 4 and 5 or web calculator (www.cvdcheck.org.au). Classify CVD absolute risk level High: greater than 15% risk of CVD within the next 5 years. Moderate: 10 15% risk of CVD within the next 5 years. Low: less than 10% risk of CVD within the next 5 years. More frequent review according to clinical context Review in 6 12 months Review in 2 years Identify all other CVD risk factors (See Box 1 on page 3). Provide lifestyle and pharmacological management strategies (if indicated) based on the patient s risk level and your clinical judgement (e.g. high risk requires more intensive interventions).* Refer to relevant management guidelines. * If you would like to explain the concept of absolute risk to your patient, please refer to the consumer booklet Know your heart and stroke risk available at: www.diabetesaustralia.com.au, www.kidney.org.au, www.strokefoundation.com.au and www.heartfoundation.org.au. Management recommendations are currently available across separate guidelines. Useful websites include www.diabetesaustralia.com.au, www.kidney.org.au, www.strokefoundation.com.au and www.heartfoundation.org.au. Page 2

What is included in CVD risk assessment? Absolute cardiovascular risk assessment will include an assessment of the factors outlined in Box 1 below. Box 1. Modifiable risk parameters Smoking status* Blood pressure* Serum lipids* Waist circumference and body mass index Nutrition Physical activity level Alcohol intake Non-modifiable risk parameters * and sex* Family history of premature CVD Social history including cultural identity, ethnicity, socioeconomic status and mental health Related conditions Diabetes Kidney function (microalbumin ± urine protein, estimate of glomerular filtration rate) Familial hypercholesterolaemia Evidence of atrial fibrillation (history, examination, electrocardiogram) * Risk parameters that are included in the absolute risk calculator, based on the Framingham Risk Equation. Alcohol is a risk factor for elevated blood pressure (which is itself a major independent determinant of risk of atherosclerotic disease), stroke and cardiomyopathy. For a full discussion of this, please see the NHMRC s Australian guidelines to reduce health risks from drinking alcohol. Risk assessment requires consideration of socioeconomic deprivation as an independent risk factor for CVD. Absolute risk of CVD calculated using the Framingham Risk Equation is likely to underestimate cardiovascular risk in socioeconomically deprived groups. Refer to National Heart Foundation of Australia s information sheet Familial hypercholesterolaemia: information for doctors. References 1. Jackson R, Lawes CM, Bennett DA, et al. Treatment with drugs to lower blood pressure and blood cholesterol based on an individual s absolute cardiovascular risk. Lancet 2005; 365: 434-441. 2. Chen L, Rogers SL, Colagiuri S, et al on behalf of the National Vascular Disease Prevention Alliance. How do the Australian guidelines for lipid-lowering drugs perform in practice? Cardiovascular disease risk in the AusDiab Study, 1999 2000. MJA 2008; 189: 319 322. Suggested citation: National Vascular Disease Prevention Alliance. Absolute cardiovascular disease risk assessment. Quick reference guide for health professionals. 2009. 2009 National Heart Foundation of Australia ISBN: 978-1-921226-39-7 PRO-076 Disclaimer: This document has been produced by the National Vascular Disease Prevention Alliance for the information of health professionals. The statements and recommendations it contains are, unless labelled as expert opinion, based on independent review of the available evidence. Interpretation of this document by those without appropriate medical and/or clinical training is not recommended, other than at the request of, or in consultation with, a relevant health professional. While care has been taken in preparing the content of this material, the National Vascular Disease Prevention Alliance and their employees cannot accept any liability, including for any loss or damage, resulting from the reliance on the content, or for its accuracy, currency and completeness. This material may be found in third parties programs or materials (including but not limited to show bags or advertising kits). This does not imply an endorsement or recommendation by the National Vascular Disease Prevention Alliance for such third parties organisations, products or services, including these parties materials or information. Any use of National Vascular Disease Prevention Alliance material by another person or organisation is done so at the user s own risk. The entire contents of this material are subject to copyright protection. Page 3

Australian cardiovascular risk charts People without diabetes Women Men Non-smoker Smoker Non-smoker Smoker 65 74 55 64 45 54 35 44 4 5 6 7 8 4 5 6 7 8 4 5 6 7 8 4 5 6 7 8 Charts in this age bracket are for use in Aboriginal and Torres Strait Islander populations only. * In accordance with Australian guidelines, patients with systolic blood pressure 180 mm Hg, or a total cholesterol of > 7.5 mmol/l, should be considered at increased absolute risk of CVD. Risk level for 5-year cardiovascular (CVD) risk High risk Moderate risk Low risk 30% 25 29% 20 24% 16 19% 10 15% 5 9% < 5% How to use the risk charts 1. Identify the chart relating to the person s sex, diabetes status, smoking history and age. The charts should be used for all adults aged 45 74 years (and all Aboriginal and Torres Strait Islander adults aged 35 years or older) without known history of CVD or already known to be at high risk. 2. Within the chart, choose the cell nearest to the person s age, systolic blood pressure (SBP) and total cholesterol (TC):HDL ratio. For example, the lower left cell contains all non-smokers without diabetes who are 35 44 years and have a TC:HDL ratio of less than 4.5 and a SBP of less than 130 mm Hg. 3. The colour of the cell that the person falls into provides their 5-year absolute cardiovascular risk level (see legend above for risk category). People who fall exactly on a threshold between cells are placed in the cell indicating higher risk. Page 4

People with diabetes Women Men Non-smoker Smoker Non-smoker Smoker 65 74 55 64 45 54 Adults over the age of 60 with diabetes are equivalent to high risk (> 15%), regardless of their calculated risk level. Nevertheless, reductions in risk factors in this age group can still lower overall absolute risk. 35 44 4 5 6 7 8 4 5 6 7 8 4 5 6 7 8 4 5 6 7 8 Charts in this age bracket are for use in Aboriginal and Torres Strait Islander populations only. * In accordance with Australian guidelines, patients with systolic blood pressure 180 mm Hg, or a total cholesterol of > 7.5 mmol/l, should be considered at increased absolute risk of CVD. Risk level for 5-year cardiovascular (CVD) risk High risk Moderate risk Low risk 30% 25 29% 20 24% 16 19% 10 15 % 5 9% < 5% Notes: The risk charts include values for SBP alone, as this is the most informative of conventionally measured blood pressure parameters for cardiovascular risk. For certain groups CVD risk may be underestimated using these charts; please see page 3 for recommendations to identify these groups. CVD refers collectively to coronary heart disease (CHD), stroke and other vascular disease including peripheral arterial disease and renovascular disease. Charts are based on the NVDPA s Guidelines for the assessment of absolute cardiovascular disease risk and adapted with permission from New Zealand Guidelines Group. New Zealand Cardiovascular Guidelines Handbook: A Summary Resource for Primary Care Practitioners. Second edition. Wellington, NZ: 2009. www.nzgg.org.nz. Page 5

Who should have their absolute cardiovascular risk assessed? * Adults aged 45-74 years without existing CVD or not already known to be at increased risk of CVD Absolute cardiovascular risk assessment, using the Framingham Risk Equation to predict risk of a cardiovascular event over the next 5 years, should be performed for all adults aged 45 74 years without existing CVD or not already known to be at increased risk of CVD (see Box 2 below). For specific population groups, additional recommendations include: 1. Commence assessment in Aboriginal and Torres Strait Islander adults at 35 years (rather than 45 years). Although the Framingham Risk Equation might underestimate risk in this population, available evidence suggests that this approach will provide an estimate of minimum cardiovascular risk. 2. Conduct assessments in adults with diabetes aged 45 60 years (rather than 45 74 years). Although the Framingham Risk Equation might underestimate risk in this population, available evidence suggests that this approach will provide an estimate of minimum cardiovascular risk. 3. In adults who are overweight or obese, the results of the assessment should be interpreted with the awareness that its predictive value has not been specifically assessed in this population. 4. In adults with atrial fibrillation (particularly those aged over 65 years), an increased risk of cardiovascular events and all-cause mortality, in addition to thromboembolic disease and stroke, should be taken into account. While CVD risk is known to be elevated for this population, it is not possible to quantify the degree of additional CVD risk in an individual. Clinical judgement is necessary when assessing overall CVD risk. Adults already known to be at increased risk of CVD Adults with any of the conditions in Box 2 are already known to be at increased absolute risk of CVD and do not require further assessment using the Framingham Risk Equation. For these groups, identifying all cardiovascular risk factors present will enable intensive management by lifestyle interventions (for all patients) and pharmacological interventions (where indicated). * Some recommendations were derived from the systematic review, while others are consensus statements developed where the systematic literature review process was undertaken, but no evidence was found for or against the recommendation. For details see NVDPA s Guidelines for the assessment of absolute cardiovascular disease risk. Refer to National Heart Foundation of Australia s information sheet Familial hypercholesterolaemia: information for doctors. Box 2. Diabetes and age > 60 years Diabetes with microalbuminuria (> 20 mcg/min or urinary albumin:creatinine ratio > 2.5 mg/mmol for males, > 3.5 mg/mmol for females) Moderate or severe chronic kidney disease (persistent proteinuria or estimated glomerular filtration rate < 45 ml/min/1.73 m 2 ) A previous diagnosis of familial hypercholesterolaemia Systolic blood pressure 180 mmhg or diastolic blood pressure 110 mmhg Serum total cholesterol > 7.5 mmol/l Page 6